Rallybio (RLYB) has provided an update.
Rallybio Corporation has entered into a significant collaboration with Johnson & Johnson to develop treatments for FNAIT, a condition affecting pregnant individuals and newborns. The partnership includes data sharing from Rallybio’s studies and an initial $0.5 million payment from J&J, with potential for $3.7 million more based on milestones. Additionally, Rallybio sold over 3.6 million shares to J&J for $6.6 million and agreed to a 180-day lock-up period on stock sales, underscoring a deepening financial and research relationship between the two companies.
For detailed information about RLYB stock, go to TipRanks’ Stock Analysis page.
